Epidermal growth factor receptor inhibitors trigger a type I interferon response in human skin

Daniela Lulli, Maria Luigia Carbone, Saveria Pastore

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The Epidermal Growth Factor Receptor (EGFR) is centrally involved in the regulation of key processes of the epithelia, including cell proliferation, survival, differentiation, and also tumorigenesis. Humanized antibodies and small-molecule inhibitors targeting EGFR were developed to disrupt these functions in cancer cells and are currently used in the treatment of diverse metastatic epithelial cancers. By contrast, these drugs possess significant skin-specific toxic effects, comprising the establishment of a persistent inflammatory milieu. So far, the molecular mechanisms underlying these epiphenomena have been investigated rather poorly. Here we showed that keratinocytes respond to anti-EGFR drugs with the development of a type I interferon molecular signature. Upregulation of the transcription factor IRF1 is early implicated in the enhanced expression of interferon-kappa, leading to persistent activation of STAT1 and further amplification of downstream interferoninduced genes, including anti-viral effectors and chemokines. When anti-EGFR drugs are associated to TNF-a, whose expression is enhanced by the drugs themselves, all these molecular events undergo a dramatic enhancement by synergy mechanisms. Finally, high levels of interferon-kappa can be observed in epidermal keratinocytes and also in leukocytes infiltrating the upper dermis of cetuximab-driven skin lesions. Our data suggest that dysregulated activation of type I interferon innate immunity is implicated in the molecular processes triggered by anti-EGFR drugs and leading to persistent skin inflammation.

Original languageEnglish
Pages (from-to)47777-47793
Number of pages17
JournalOncotarget
Volume7
Issue number30
DOIs
Publication statusPublished - 2016

Fingerprint

Interferon Type I
Epidermal Growth Factor Receptor
Skin
Pharmaceutical Preparations
Keratinocytes
Antibodies, Monoclonal, Humanized
Poisons
Dermis
Chemokines
Innate Immunity
Neoplasms
Cell Survival
Carcinogenesis
Leukocytes
Transcription Factors
Up-Regulation
Epithelium
Cell Proliferation
Inflammation
Genes

Keywords

  • Anticancer drug
  • Antiviral innate immunity
  • Chemokine
  • Transcriptome profiling
  • Tumor necrosis factor alpha

ASJC Scopus subject areas

  • Oncology

Cite this

Epidermal growth factor receptor inhibitors trigger a type I interferon response in human skin. / Lulli, Daniela; Carbone, Maria Luigia; Pastore, Saveria.

In: Oncotarget, Vol. 7, No. 30, 2016, p. 47777-47793.

Research output: Contribution to journalArticle

Lulli, Daniela ; Carbone, Maria Luigia ; Pastore, Saveria. / Epidermal growth factor receptor inhibitors trigger a type I interferon response in human skin. In: Oncotarget. 2016 ; Vol. 7, No. 30. pp. 47777-47793.
@article{fa6fe33cd85f4362b7ca77f9cb46c30d,
title = "Epidermal growth factor receptor inhibitors trigger a type I interferon response in human skin",
abstract = "The Epidermal Growth Factor Receptor (EGFR) is centrally involved in the regulation of key processes of the epithelia, including cell proliferation, survival, differentiation, and also tumorigenesis. Humanized antibodies and small-molecule inhibitors targeting EGFR were developed to disrupt these functions in cancer cells and are currently used in the treatment of diverse metastatic epithelial cancers. By contrast, these drugs possess significant skin-specific toxic effects, comprising the establishment of a persistent inflammatory milieu. So far, the molecular mechanisms underlying these epiphenomena have been investigated rather poorly. Here we showed that keratinocytes respond to anti-EGFR drugs with the development of a type I interferon molecular signature. Upregulation of the transcription factor IRF1 is early implicated in the enhanced expression of interferon-kappa, leading to persistent activation of STAT1 and further amplification of downstream interferoninduced genes, including anti-viral effectors and chemokines. When anti-EGFR drugs are associated to TNF-a, whose expression is enhanced by the drugs themselves, all these molecular events undergo a dramatic enhancement by synergy mechanisms. Finally, high levels of interferon-kappa can be observed in epidermal keratinocytes and also in leukocytes infiltrating the upper dermis of cetuximab-driven skin lesions. Our data suggest that dysregulated activation of type I interferon innate immunity is implicated in the molecular processes triggered by anti-EGFR drugs and leading to persistent skin inflammation.",
keywords = "Anticancer drug, Antiviral innate immunity, Chemokine, Transcriptome profiling, Tumor necrosis factor alpha",
author = "Daniela Lulli and Carbone, {Maria Luigia} and Saveria Pastore",
year = "2016",
doi = "10.18632/oncotarget.10013",
language = "English",
volume = "7",
pages = "47777--47793",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "30",

}

TY - JOUR

T1 - Epidermal growth factor receptor inhibitors trigger a type I interferon response in human skin

AU - Lulli, Daniela

AU - Carbone, Maria Luigia

AU - Pastore, Saveria

PY - 2016

Y1 - 2016

N2 - The Epidermal Growth Factor Receptor (EGFR) is centrally involved in the regulation of key processes of the epithelia, including cell proliferation, survival, differentiation, and also tumorigenesis. Humanized antibodies and small-molecule inhibitors targeting EGFR were developed to disrupt these functions in cancer cells and are currently used in the treatment of diverse metastatic epithelial cancers. By contrast, these drugs possess significant skin-specific toxic effects, comprising the establishment of a persistent inflammatory milieu. So far, the molecular mechanisms underlying these epiphenomena have been investigated rather poorly. Here we showed that keratinocytes respond to anti-EGFR drugs with the development of a type I interferon molecular signature. Upregulation of the transcription factor IRF1 is early implicated in the enhanced expression of interferon-kappa, leading to persistent activation of STAT1 and further amplification of downstream interferoninduced genes, including anti-viral effectors and chemokines. When anti-EGFR drugs are associated to TNF-a, whose expression is enhanced by the drugs themselves, all these molecular events undergo a dramatic enhancement by synergy mechanisms. Finally, high levels of interferon-kappa can be observed in epidermal keratinocytes and also in leukocytes infiltrating the upper dermis of cetuximab-driven skin lesions. Our data suggest that dysregulated activation of type I interferon innate immunity is implicated in the molecular processes triggered by anti-EGFR drugs and leading to persistent skin inflammation.

AB - The Epidermal Growth Factor Receptor (EGFR) is centrally involved in the regulation of key processes of the epithelia, including cell proliferation, survival, differentiation, and also tumorigenesis. Humanized antibodies and small-molecule inhibitors targeting EGFR were developed to disrupt these functions in cancer cells and are currently used in the treatment of diverse metastatic epithelial cancers. By contrast, these drugs possess significant skin-specific toxic effects, comprising the establishment of a persistent inflammatory milieu. So far, the molecular mechanisms underlying these epiphenomena have been investigated rather poorly. Here we showed that keratinocytes respond to anti-EGFR drugs with the development of a type I interferon molecular signature. Upregulation of the transcription factor IRF1 is early implicated in the enhanced expression of interferon-kappa, leading to persistent activation of STAT1 and further amplification of downstream interferoninduced genes, including anti-viral effectors and chemokines. When anti-EGFR drugs are associated to TNF-a, whose expression is enhanced by the drugs themselves, all these molecular events undergo a dramatic enhancement by synergy mechanisms. Finally, high levels of interferon-kappa can be observed in epidermal keratinocytes and also in leukocytes infiltrating the upper dermis of cetuximab-driven skin lesions. Our data suggest that dysregulated activation of type I interferon innate immunity is implicated in the molecular processes triggered by anti-EGFR drugs and leading to persistent skin inflammation.

KW - Anticancer drug

KW - Antiviral innate immunity

KW - Chemokine

KW - Transcriptome profiling

KW - Tumor necrosis factor alpha

UR - http://www.scopus.com/inward/record.url?scp=84982851832&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982851832&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.10013

DO - 10.18632/oncotarget.10013

M3 - Article

VL - 7

SP - 47777

EP - 47793

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 30

ER -